Tweet
Am J Transplant
. 2023 Oct 18:S1600-6135(23)00789-X.
doi: 10.1016/j.ajt.2023.09.022. Online ahead of print. Clinical characteristics and outcomes of liver transplant recipients infected by Omicron during the opening up of the dynamic zero-COVID policy in China: a prospective, observational study
Wei Zhang 1 , Rongrong Wang 2 , Pingbo Jin 1 , Xinyu Yu 1 , Weili Wang 1 , Yuntao Zhang 1 , Xueli Bai 1 , Tingbo Liang 3
Affiliations
We analyzed the characteristics, risk factors, outcomes, and post-coronavirus disease 2019 (COVID-19) symptoms in liver transplant recipients in China's late 2022 COVID-19 wave. Recipients with COVID-19 were enrolled from December 1, 2022 to January 31, 2023, and followed up until May 31, 2023. Baseline and characteristic data were collected. A total of 930 recipients were included, with a vaccination rate (non-mRNA) of 40.0%. Among 726 (78.1%) recipients with COVID-19, 641 (88.3%) patients were treated at home, 81 (11.2%) patients required hospitalization in general wards, four (0.6%) patients required intensive care, and one (0.1%) patient died because of COVID-19. SARS-CoV-2 infection was related to close contact with confirmed cases (p < 0.001) and the condition of end-stage kidney disease (p < 0.046). Older age, male sex, less vaccination, and hypertension were independent risk factors for hospitalization. Fatigue (36.9%) was the most common symptom post-COVID-19, followed by memory loss (35.7%) and sleep disturbance (23.9%). Two doses of vaccines had a protective effect against these post-COVID-19 symptoms (p < 0.05). During this Omicron outbreak, liver transplant recipients were susceptible to COVID-19, with frequent hospitalization but low mortality. Two doses of non-mRNA COVID-19 vaccines could protect against liver transplant recipient hospitalization and post-COVID-19 symptoms.
Keywords: COVID-19; Characteristics; Omicron; liver transplant; outcomes; risk factors.
. 2023 Oct 18:S1600-6135(23)00789-X.
doi: 10.1016/j.ajt.2023.09.022. Online ahead of print. Clinical characteristics and outcomes of liver transplant recipients infected by Omicron during the opening up of the dynamic zero-COVID policy in China: a prospective, observational study
Wei Zhang 1 , Rongrong Wang 2 , Pingbo Jin 1 , Xinyu Yu 1 , Weili Wang 1 , Yuntao Zhang 1 , Xueli Bai 1 , Tingbo Liang 3
Affiliations
- PMID: 37863433
- DOI: 10.1016/j.ajt.2023.09.022
We analyzed the characteristics, risk factors, outcomes, and post-coronavirus disease 2019 (COVID-19) symptoms in liver transplant recipients in China's late 2022 COVID-19 wave. Recipients with COVID-19 were enrolled from December 1, 2022 to January 31, 2023, and followed up until May 31, 2023. Baseline and characteristic data were collected. A total of 930 recipients were included, with a vaccination rate (non-mRNA) of 40.0%. Among 726 (78.1%) recipients with COVID-19, 641 (88.3%) patients were treated at home, 81 (11.2%) patients required hospitalization in general wards, four (0.6%) patients required intensive care, and one (0.1%) patient died because of COVID-19. SARS-CoV-2 infection was related to close contact with confirmed cases (p < 0.001) and the condition of end-stage kidney disease (p < 0.046). Older age, male sex, less vaccination, and hypertension were independent risk factors for hospitalization. Fatigue (36.9%) was the most common symptom post-COVID-19, followed by memory loss (35.7%) and sleep disturbance (23.9%). Two doses of vaccines had a protective effect against these post-COVID-19 symptoms (p < 0.05). During this Omicron outbreak, liver transplant recipients were susceptible to COVID-19, with frequent hospitalization but low mortality. Two doses of non-mRNA COVID-19 vaccines could protect against liver transplant recipient hospitalization and post-COVID-19 symptoms.
Keywords: COVID-19; Characteristics; Omicron; liver transplant; outcomes; risk factors.